CompoAtlas

DESMODIUM 2000 DETOXIFIANT DU FOIE

Food supplement declared in France, declaration No 2018-6-416

DESMODIUM 2000 DETOXIFIANT DU FOIE is a food supplement declared in France. Status: retiré du marché le 5 November 2024. 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
SANTAROME SAS
Status
Retiré du marché le 5 November 2024
Form
Ampoule
Daily dose
1 ampoule par jour
Directions for use
1 ampoule par jour le matin à diluer dans un verre d’eau
Not recommended for (according to the manufacturer)
Femmes allaitantes, Allergie aux dérivés salicylés, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Insuffisance rénale, Nourrissons (moins de 1 an), Sous anticoagulants, Utilisation prolongée
Objectives stated by the manufacturer (these are not authorised claims)
Détoxifiant / Draineur

Declaration 289280, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Desmodium adscendens (Sw.) DC.FeuilleExtrait fluide aqueux8,000 mg
Betula pubescens Ehrh.BourgeonMacérât hydroglycériné50 mg
Juniperus communis L.Jeune pousseMacérât hydroglycériné50 mg
Rosmarinus officinalis L.Jeune pousseMacérât hydroglycériné50 mg

Other ingredients

Eau purifiée

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé aux enfants de moins de 12 ans, femmes enceintes ou allaitantes ainsi qu’aux personnes souffrant d’allergie aux dérivés salicylés ou sous traitement anticoagulant. Ne pas utiliser en cas d'insuffisance rénale ni de manière prolongée (maximum 6 semaines).

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Betula pubescens Ehrh.
    Read the warning, when it applies and the studies cited

    Birch

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney or cardiovascular disorders (Brinker 2010; Bradley 2006; ESCOP 2003; Blumenthal et al. 1998).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 28 August 2024

  • Juniperus communis L.
    Read the warning, when it applies and the studies cited

    Juniper - Juniperus Communis

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Mills et al. 2006).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are pregnant (Brinker 2010; Bradley 2006; ESCOP 2003; Hoffmann 2003).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have a kidney disorder (Brinker 2010; Bradley 2006; ESCOP 2003; Hoffmann 2003).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 January 2025

  • Rosmarinus officinalis L.
    Read the warning, when it applies and the studies cited

    ROSEMARY – ROSMARINUS OFFICINALIS Oral

    Route of administration: Oral (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

    ROSEMARY - ROSMARINUS OFFICINALIS Topical

    Route of administration: Topical (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line